🌐 ICATM Consortium

← Back to Qualification Pathways

Overview

The International Cooperation on Alternative Test Methods (ICATM) is a unique multi-stakeholder consortium that coordinates validation activities and promotes mutual acceptance of alternative test methods across regulatory agencies, industry, and research organizations worldwide. Established in 2000 and coordinated by the OECD, ICATM brings together regulators from 40+ countries, industry partners, academic researchers, and technology developers to harmonize NAMs validation approaches and accelerate global acceptance.

Unlike formal regulatory programs (FDA ISTAND, EMA SAWP) managed by individual agencies, ICATM functions as a horizontal coordination network where validation activities are conducted collaboratively and results are shared across participating regulatory systems. This consortium model enables cost-sharing, risk distribution, and simultaneous regulatory acceptance across multiple jurisdictions, making it uniquely attractive for truly global technologies.

ICATM Member Categories

Governmental Members (Regulatory Agencies)

National regulatory authorities representing 40+ countries across EU, North America, Asia, and emerging markets. Members include FDA (USA), EMA (Europe), MHRA (UK), Health Canada, PMDA (Japan), NMPA (China), TGA (Australia), and others. Each regulatory member brings enforcement authority and commits to mutually accepting validated ICATM methods in their jurisdictions.

Industry Members (Technology Developers & Pharmaceutical Companies)

Companies developing or implementing NAMs technologies. Members include organ-on-chip companies (Emulate, CN Bio, Mimetas), organoid platforms (Organovo, Insphero), CROs (Charles River, Parexel), and major pharma (Roche, GSK, AbbVie). Industry members fund validation projects, contribute technical expertise, and benefit from validated methods for development programs.

Observer Members (Academic Institutions, NGOs, Consultants)

Academic research centers, non-profit organizations, and consulting firms that participate in discussions and contribute scientific expertise. Observers include universities, research institutes, animal welfare organizations, and technology vendors. This category enables broad stakeholder input while maintaining core governance structure.

ICATM Governing Structure

The ICATM Validation Pathway

Phase 1: Method Identification & Feasibility (Months 0-6)

ICATM working groups identify promising methods addressing regulatory needs. Method must: (1) address genuine gap in current testing approaches, (2) have preliminary scientific evidence of relevance, (3) have willing technology developer/sponsor, (4) have committed funding sources. Working group conducts preliminary assessment and creates validation roadmap.

Phase 2: Detailed Validation Protocol Development (Months 6-12)

Expert panel develops comprehensive international validation protocol specifying: (1) reference chemical selection (50-200+ compounds), (2) laboratory testing procedures and quality standards, (3) statistical analysis methods and acceptance criteria, (4) inter-laboratory coordination procedures, (5) timeline and cost projections, (6) roles and responsibilities of participating laboratories.

Phase 3: Multi-Laboratory Validation Studies (Months 12-36)

Coordinated validation across 4-10 international laboratories (CROs, academic centers, industry labs) in different countries. Each lab independently tests reference chemicals per validated protocol. Continuous data sharing and quality assurance. ICATM coordinates activities and tracks progress toward validation milestones.

Phase 4: Data Integration and Analysis (Months 30-42)

Expert statisticians integrate data from all participating laboratories. Conduct meta-analysis demonstrating method reliability, relevance, and transferability. Prepare integrated results showing method performance across geographies and laboratory types. Identify any outliers or procedural deviations requiring resolution.

Phase 5: Peer Review (Months 42-48)

Independent expert panel reviews complete validation dossier. Panel assesses against OECD principles for test guideline development (relevance, reliability, transferability, regulatory acceptance). Panel provides detailed feedback and recommendations for final method documentation.

Phase 6: Final Guidance Development (Months 48-54)

Based on peer review, expert panel develops final Test Guideline or ICATM guidance document. Document specifies method principles, procedures, expected performance, limitations, and contexts of use. Prepares background review document explaining scientific basis and validation results.

Phase 7: Publication & Global Implementation (Months 54+)

OECD publishes validated method as official Test Guideline (if pursuing full OECD status) or as formal ICATM guidance. Method becomes immediately available for regulatory use across all participating member countries. Member countries integrate into national regulations and guidance documents.

Cost-Sharing and Funding Model

ICATM operates on a cost-sharing consortium model where validation expenses are distributed across multiple organizations:

Per-Organization Cost: Typically $100-200K per participating company vs $1-3M for individual case-by-case qualification or $3-8M for FDA ISTAND. Regulatory agencies contribute resources in-kind (staff time, decision-making authority, priority in review queues).

Competitive Advantages of ICATM Participation

• Global Regulatory Acceptance: Single validation automatically accepted across 40+ regulatory jurisdictions
• Dramatically Reduced Per-Company Cost: $100-200K/company vs $1-3M for single-jurisdiction qualification
• Risk Distribution: Multiple organizations share development and regulatory risk
• Accelerated Timeline: Parallel efforts across multiple laboratories shorten overall validation duration
• Scientific Rigor: Multi-laboratory, multi-regulatory jurisdiction validation provides highest scientific credibility
• Regulatory Certainty: Direct involvement of regulatory agencies ensures method acceptability before full commitment
• Ongoing Support: OECD provides long-term stewardship and updates to methods as science evolves
• Market Differentiation: Early adoption and participation in ICATM provides competitive advantage for first-mover technologies

Success Stories: Methods Validated Through ICATM

In Vitro Skin Irritation (OECD TG 439 - Reconstructed Epidermis)

ICATM coordinated 8-laboratory international validation of reconstructed human epidermis models (EpiSkin, EpiDerm, LabSkin) for skin irritation prediction. Validation involved 40+ reference chemicals tested across laboratories in US, EU, Japan, and other countries. Results demonstrated comparable or superior performance to animal tests. Now fully adopted as official OECD Test Guideline with global regulatory acceptance for cosmetics and chemicals safety assessment. Represents landmark success reducing animal testing in cosmetics industry.

In Vitro Eye Irritation (OECD TG 492 - Reconstructed Cornea)

ICATM coordinated 6-laboratory validation of reconstructed human cornea model (EpiOcular) for eye irritation classification. Validation included 35 reference chemicals with diverse irritancy profiles. Resulted in official OECD Test Guideline now used for chemical safety assessment. Multiple companies invested in commercial production and regulatory acceptance of method.

In Vitro Acute Systemic Toxicity (Multiple OECD TGs)

ICATM facilitated development of multiple OECD Test Guidelines for in vitro acute toxicity methods (TG 439, 492, 438, etc.). These methods collectively reduce reliance on animal LD50 tests for cosmetics, chemicals, and pharmaceuticals. Coordinated validation involved 50+ laboratories across member countries.

Current ICATM NAMs Projects (In Development)

• 3D Liver Models - Coordinating international validation of organoid and organ-on-chip liver systems for hepatotoxicity
• Immunotoxicity Assessment - Multi-laboratory validation of in vitro immune system models
• Reproductive/Developmental Toxicity - Coordinating validation of iPSC-derived developmental models
• Neurotoxicity Screening - International consortium validating neural organoid and microphysiological systems
• Computational Toxicology - ICATM guidance development for AI/ML-based toxicity prediction models

How Organizations Join ICATM

Membership Application Process

1. Contact OECD Task Force Secretariat expressing interest in ICATM membership
2. Specify member category (governmental, industry, observer) and intended role
3. Participate in working group meetings (some as observer to assess fit)
4. Formal application submission with organizational description and commitment letter
5. Steering Committee review and approval (typically 2-3 months)
6. Formal membership activation and participation in working group activities

Sponsoring a Method Through ICATM

To propose a new NAMs method for ICATM validation:

1. Present method to relevant ICATM working group with preliminary data
2. Work with group to develop detailed validation protocol and feasibility assessment
3. Identify international laboratories willing to participate in validation
4. Commit funding and resources (typically $100-250K for technology developers)
5. Participate in 2-4 year validation process as active team member
6. Collaborate on publication and implementation planning
7. Benefit from global regulatory acceptance upon successful validation

ICATM vs Other Qualification Pathways

Implementation Roadmap for ICATM Participation

1. Assess Method Readiness (0-3 months) - Evaluate whether method meets ICATM criteria and is ready for international validation
2. Identify Relevant ICATM Working Group (3-6 months) - Determine which group aligns with method application
3. Preliminary Engagement (6-9 months) - Attend working group meetings as observer; present method informally
4. Apply for ICATM Membership (9-12 months) - Submit formal membership application (if not already member)
5. Develop Validation Protocol (12-18 months) - Work with working group to design detailed protocol
6. Secure Commitments (18-24 months) - Identify partner laboratories; secure funding commitments from industry and regulatory sponsors
7. Formal Project Approval (24 months) - ICATM Steering Committee formally approves validation project
8. Launch Multi-Lab Validation (24-36 months) - Begin coordinated testing across international laboratories
9. Ongoing Coordination (30-42 months) - Active project management, quarterly progress reviews, troubleshooting
10. Data Integration & Analysis (36-48 months) - Compile results, conduct meta-analysis, prepare statistical summaries
11. Expert Peer Review (42-54 months) - Independent review of validation dossier
12. Finalize Guidance (48-54 months) - Develop final Test Guideline or formal guidance document
13. OECD Publication (54+ months) - Official publication as OECD Test Guideline or ICATM guidance

Resources and Further Information

• OECD ICATM Homepage - Official program information and member contacts
• OECD Environment, Health & Safety Division - Test Guidelines and regulatory information
• Qualification Pathways - Comparison of all NAMs validation approaches
• Technology Overview - Learn about NAMs platforms eligible for ICATM validation
• Science Section - Technical details on alternative methods

← Back to Qualification Pathways